Provided by Tiger Trade Technology Pte. Ltd.

VanEck Biotech ETF

242.35
-1.3764-0.56%
Volume:2K
Turnover:540.98K
Market Cap:479.01M
PE:- -
High:242.41
Open:242.41
Low:242.26
Close:243.73
52wk High:244.35
52wk Low:160.91
Shares:1.98M
Float Shares:1.98M
Volume Ratio:0.33
T/O Rate:0.11%
Dividend:0.95
Dividend Rate:0.39%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Gilead : Leerink Partners Raises Target Price to $130 from $126

THOMSON REUTERS
·
Aug 05

Amgen Inc : Scotiabank Raises Target Price to $450 from $385

THOMSON REUTERS
·
Aug 05

Gilead Sciences (GILD) Gets a Buy from Wells Fargo

TIPRANKS
·
Aug 05

Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained

TIPRANKS
·
Aug 05

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries

Reuters
·
Aug 05

Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong

Dow Jones
·
Aug 05

Street View: Amgen Builds Momentum with Blockbusters, Biosimilars and a Pipeline in Waiting

Reuters
·
Aug 05

Amgen Inc : Morgan Stanley Raises Target Price to $351 from $333

THOMSON REUTERS
·
Aug 05

Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth

Reuters
·
Aug 05

Amgen Inc : Oppenheimer Raises Target Price to $450 from $400

THOMSON REUTERS
·
Aug 05

Gilead : Truist Securities Cuts Target Price to $150 from $156

THOMSON REUTERS
·
Aug 05

Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million

Reuters
·
Aug 05

Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...

Dow Jones
·
Aug 05

Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion

Reuters
·
Aug 05

Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million

Reuters
·
Aug 05

Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains

Reuters
·
Aug 05

Amgen Announces Availability of Q2 2026 Earnings Report Release

Reuters
·
Aug 05

Amgen's Strong Second Quarter Drug Sales Drive Upward Forecast Revision and Early-Stage Weight Loss Drug Termination

Deep News
·
Aug 05

Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth

Deep News
·
Aug 05